ORNITHODOROS MOUBATA AND COMPLEMENT INHIBITOR FOR TREATING COMPLEMENT-MEDIATED DISEASES OF PATIENT WITH COMPLEMENT C5 POLYMORPHISM Russian patent published in 2019 - IPC A61K38/17 A61P7/00 A61P37/00 

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine and concerns a method of treating or preventing a complement-mediated disease and/or disorder involving administering to a subject having complement polymorphism C5 and requiring such administration, therapeutically or prophylactically effective amount of an agent which inhibits the classical complement pathway, an alternative complement pathway and complement lectin pathway, wherein the agent is: (a) a protein comprising or consisting of amino acids 19–168 of the amino acid sequence SEQ ID NO: 2, or is a functional equivalent of such protein; (b) a protein comprising or consisting of amino acids 1–168 of the amino acid sequence SEQ ID NO: 2, or is a functional equivalent of such protein; or (c) a nucleic acid molecule encoding a protein specified in (a) or (b); and where complement polymorphism C5 lowers the effectiveness of ekulizumab. Group of inventions also relates to the use of an agent which inhibits a classical complement pathway, an alternative complement pathway and a lectin complement pathway for treating or preventing a complement-mediated disease and/or disorder in a subject having complement C5 polymorphism.

EFFECT: group of inventions provides treating or preventing a complement-mediated disease and/or disorder in a subject having C5 complement polymorphism.

14 cl, 8 dwg, 5 ex